Researchers in the U.K. have the first estimates for how long a third shot of the Pfizer vaccine will last. The findings are mixed.
Moderna said its current FDA-approved 50-microgram booster shot increased antibody levels against omicron 37-fold compared to pre-booster levels.
Omicron has many more mutations than previous variants of concern, a fact that raises questions about how effective existing vaccines will be against the new form of the coronavirus.
Does a booster shot mean that you can go back to ... normal? Or is there still a newish kind of normal to face?
Moderna says the FDA is looking into reports of a rare side effect — myocarditis, or the inflammation of the heart muscle — in those who've gotten the shot.
The U.S. has pledged to deliver 1.1 billion doses of COVID vaccines to countries in need. Billions more are needed. NPR interviewed the State Department's global vaccine coordinator to learn more.
CDC Director Rochelle Walensky also endorsed a mix-and-match approach to boosters that would be flexible for patients and health care providers.
The Food and Drug Administration also gave an OK to boosters that differ from the vaccine originally used to immunize people against COVID-19. A mix-and-match approach could ease the booster rollout.
It's the first step in an audacious plan to solve vaccine inequity by setting up the manufacturing of mRNA vaccines across low-resource countries,
"I knew I had wanted to do something with light because I felt like it's just been such a dark year and a half that I wanted to bring light to whatever it was I was doing," Laura Weiss told NPR.
A source familiar with the discussions says administration health experts could make the recommendation for fully vaccinated adults as soon as this week.
The delta variant is the fast-moving strain of the coronavirus now found in 96 countries. It's expected to be the dominant variant in the U.S. within weeks.
Oxford-AstraZeneca promised its COVID-19 vaccine would be effective, cheap and available worldwide. Five months after its launch, the path forward has been anything but smooth.
One of the hottest areas of research right now: studies to determine how well current vaccines work against emerging coronavirus "variants of concern."